


Diabetes Meds for Type 2: Objectives





- 1. Describe the main action of the different categories of type 2 diabetes medications.
- 2. Discuss using the AACE and ADA 2015 Guidelines to determine best therapeutic approach.
- 3. Using the ADA Guidelines, describe strategies to initiate and adjust insulin therapy.












Antihyperglycemic Therapy – 1st Step

- ▶ Lifestyle Changes
 - ▶ Weight control
 - ▶ Healthy eating
 - ▶ Activity



ADA-EASD Position Statement: Management of Hyperglycemia in T2DM

Diabetes Care 2012;35:1364–1379 Diabetologia 2012;55:1577–1596



Patient Centered Approach


- "...providing care that is respectful of and responsive to individual patient preferences, needs, and values ensuring that patient values guide all clinical decisions."
- Gauge patient's preferred level of involvement.
- Explore, where possible, therapeutic choices.
- Utilize decision aids.
- <u>Shared</u> decision making final decisions re: lifestyle choices ultimately lie with the patient.


ADA-EASD Position Statement: Management of Hyperglycemia in T2DM Diabetes Care 2012;35:1364–1379 Diabetologia 2012;55:1577–1596





Diabetes Education Services© 1998-2015






Glycemic Targets - ADA

▶ Adult non pregnant A1c goals


- ▶ A1c < 7% a reasonable goal for adults.
- ▶ A1c < 6.5% may be appropriate for those without significant risk of hypoglycemia or other adverse effects of treatment.
- ▶ A1c < 8% may be appropriate for patients with history of hypoglycemia, limited life expectancy, or those with longstanding diabetes and vascular complications.











Treating Hyperglycemia with Meds

➤ For all of the following case studies, we assume we are providing ongoing education on lifestyle — including referral to a RD and diabetes educator.



▶ In describing what meds match the patient best, I am speaking as an advocate for patients and a consultants to providers.






Class/Main Action	Name(s)	Daily Dose Range	Considerations		
Biguanides	metformin (Glucophage)	500 - 2500 mg (usually BID w/meal)	Side effects: nausea, bloating, diarrhea. Use XR to minimize. Lactic acidosis precaution:		
Decrease hepatic glucose output First line med at diagnosis of type 2	Extended Release-XR (Glucophage XR) (Glumetza) (Fortamet)	(1x daily w/dinner) 500 – 2000 mg 500 – 2000 mg 500 – 2500 mg	avoid in pts with creat >1.4 women, 1.5 men, during illness or surgery. Benefits: decreased cholesterol, no wt gain or hypoglycemia. Lowers A1c 1.0% – 2.0%.		
Sulfonylureas	glyburide: (Micronase, Diabeta) (Glynase)	1.25 – 20 mg 0.75 – 12 mg	Can take once or twice daily before meals. Side effects include hypoglycemia and weight gain. Eliminated via kidney.		
Stimulates sustained insulin release	glipizide: (Glucotrol) (Glucotrol XL)	cotrol) 2.5 – 40 mg Caution: Glyburide most likely cause hypoglycemia.	Caution: Glyburide most likely to cause hypoglycemia.		
	glimepiride (Amaryl)	1.0 – 8 mg	Lowers A1c 1.0% – 2.0%.		
DPP – 4 Inhibitors	sitagliptin (Januvia)	100 mg daily (eliminated via kidney*)	"If creatinine elevated, see pkg insert for dosing info. No wt gain or hypoglycemia. Side effects include nasopharyngitis, headache and upper-respiratory tract infection. Report signs of pancreatitis (abdominal pain, nausea, vomiting). Lowers A1c 0.6% – 0.8%.		
"Incretin Enhancers" Prolongs action of gut	saxagliptin (Onglyza)	Up to 5 mg daily (eliminated via kidney*, feces)			
hormones Increases insulin secretion	linagliptin (Tradjenta)	5 mg daily (eliminated via feces)			
Delays gastric emptying	alogliptin (Nesina)	25 mg once daily (eliminated via kidney)			

Class/Main Action	Name(s)	Daily Dose Range	Considerations
SGLT2 Inhibitors • Decrease glucose reabsorption in kidneys • "Glucoretic"	Canagliflozin (Invokana) Dapagliflozin (Farxiga) Empagliflozin (Jardiance)	100 – 300 mg 1x daily 5 – 10 mg 1x daily 10 – 25 mg 1x daily	For all, monitor B/P, K+ and renal function. If GFR<45, stop Invokana. If GFR<60, stop Farxiga. Do not start pts w/ GFR<45 on Jardiance. Side effects: hypotension, UTIs, increased urination, genital infections. Avoid Farxiga in pts w/ bladder cancer. Lowers A1c 0.7% – 1.5%, lowers wt 1 – 3 lbs.
Thiazolidinediones "TZDs" • Increase insulin sensitivity	pioglitazone (Actos) rosiglitazone (Avandia)	15 – 45 mg daily 4 – 8 mg daily	Black Box Warning: TZDs may cause or worsen CHF. Monitor for edema and weight gain. Increased peripheral fracture risk. Actos may increase risk of bladder cancer. Lowers A1c 0.5% – 1.0%
Glucosidase Inhibitors Delay carb absorption	acarbose (Precose) miglitol (Glyset)	25 – 100 mg w/meals; 300 mg max daily dose	Start low dose, increase at 4-8 wk intervals to decrease GI effects. Caution with liver or kidney problems. In case of hypo, treat w/ glucose tabs. Lowers A1c 0.5– 1.0%.
Dopamine Receptor Agonists • Resets circadian rhythm	bromocriptine mesylate— Quick Release "QR" (Cycloset)	1.6 to 4.8 mg a day (each tab 0.8 mg)	Take within 2 hrs of waking. Side effects: nausea, headache, fatigue, hypotension, syncope, somnolence. Lowers A1c 0.6% – 0.9%.
Meglitinides • Stimulates rapid insulin	repaglinide (Prandin)	0.5 – 4 mg w/meals (metabolized in liver)	Take before meals. Side effects may include hypoglycemia and weight gain.
burst	60 – 120 mg w/meals	Lowers A1c 1.0% – 2.0%.	
Diabetes Educ	Advancing in Diabetes		Diabetes Education Services (530) 893-8635 abetesEd.net Beverly Dyck Thomassian RN, MPH, BC-ADM, CDE

		Dose Range	Considerations	
GLP-1 Agonist "Incretin Mimetic" Increase insulin release with food Slows gastric emptying Promotes satiety Suppresses glucagon Lowers A1c 0.5 – 1.6% Wt loss of ~ 3lbs	exenatide (Byetta) exenatide XR (Bydureon)	5 or 10 mcg BID (renally excreted) 2mg 1x a week (renally excreted)	Side effects for all: Nausea, vomiting, weight loss, injection site reaction. Report signs of acute pancreatitis (severe abdominal pain, vomiting), stop med. Black box: Thyroid C-cell tumor warning for liraglutide, exenatide XR, alibiglutide, and dulaglutide (avoid if family history of medullary thyroid	
	liraglutide (Victoza)	0.6 - 1.8 mg daily		
	albiglutide (Tanzeum)	30 and 50 mg 1x a week pen injector		
	dulaglutide (Trulicity)	0.75 and 1.5 mg 1x a week pen injector	cancer, notify MD of hoarseness, throat lump).	
Amylin Mimetic Slows gastric emptying Supresses glucagon Promotes satiety owers A1c 0.5 – 1%	pramlintide (Symlin)	Type 1: 15 - 60 mcg; Type 2: 60 - 120 mcg immediately before major meals	For Type 1 or 2 on insulin. Black box warning: severe hypoglycemic risk 3 hrs post injection. Prevent hypoglycemia, decrease insulin dose when starting pramlintide. Side effects: nausea, weight loss.	
Slows gastric emptying Supresses glucagon Promotes satiety		Type 2: 60 - 120 mcg immediately before major meals	Black box warning: severe hypoglycemic risk 3 hrs post injection Prevent hypoglycemia, decrease insu dose when starting pramlintide. Side	



- ▶ 61 year old overweight woman with type 2 diabetes 3 months. Has been trying to control diabetes with diet and exercise. GFR in 90s. Worried about weight gain.
- ▶ Most recent A1c 6.9%
 - ▶ ADA
 - ▶ AACE
 - Cash pay








ADA Step Wise Approach to Hyperglycemia 2015

- ▶ Start with lifestyle coaching
- When lifestyle alone is not achieving A1c goal – Metformin should be added at, or soon after diagnosis (unless contraindicated).
- Metformin has a long standing evidence base for efficacy and safety, is cheap and may reduce CV risk.







When goal is to avoid weight gain

- ▶ These meds are weight neutral
 - ▶ Metformin
 - ▶ DPP-IV Inhibitors: Januvia, Onglyza, Tradjenta, Nesina
 - ▶ Acarbose



- ▶ These meds associated with wt loss
 - ▶ GLP-1 agonists (Byetta, Bydureon, Victoza, Tanzeum, Trulicity)
 - ► SGLT-2 Inhibitors (Canagliflozin, Dapagliflozin, Empagliflozin)
 - Symlin (Pramlintide)






When goal is to minimize cost

- ▶ Go generic.
- ▶ Oral Meds -Metformin and Sulfonylureas
 - ▶ Walmart offers 3 mo supply of following meds for ~ \$10
 - Metformin and Metformin XR
 - ▶ Glipizide, Glyburide, Glimepiride
- ▶ Insulins Oldies but Goodies
 - ▶ NPH, Regular, 70/30 mix
 - ▶ \$25 a vial at Walmart ReliOn
 - Vials and needles cheaper









- ▶ 61 year old overweight woman with type 2 diabetes 3 months. Has been trying to control diabetes with diet and exercise. GFR in 90s. Worried about weight gain.
- ▶ Most recent A1c 6.9%
 - ▶ ADA
 - ▶ AACE
 - Cash pay
- ▶ Solutions?
 - ▶ Start no meds and monitor (ADA)
 - ▶ Start Metformin 500 mg 1-2 x a day





Life Study

- ▶ 54 year old smoker, creatinine 1.2, BMI 27. Not checking BG, even though he has glucose meter. On Metformin 500mg BID for past 4 months. Had bad experience with hypoglycemia on glyburide.
- ▶ Most recent A1c 7.9%
 - ▶ ADA
 - ▶ AACE





Diabetes Education


When goal is to avoid Hypoglycemia


- ▶ Avoid sulfonylureas
- ▶ Careful insulin dosing
- ▶ May need to up adjust glucose goals
- ▶ Monitor kidney function
- ▶ Reinforce for patients on insulin to "TIE"
 - ▶ Test
 - ▶ Inject
 - ▶ Eat











- ▶ 54 year old smoker, creatinine 1.2, BMI 27. Not checking BG, even though he has glucose meter. On Metformin 500mg BID for past 4 months. Had bad experience with hypoglycemia on glyburide.
- ▶ Most recent A1c 7.9%
- ▶ Solution:
 - ▶ Change to Metformin XR and double dose
 - ▶ Add SGLT-2 or
 - ▶ Add GLP-1

If cash pay consider adding SU or insulin







▶ 71 year old woman with type 2 diabetes for past year. BMI 24. Has been trying to control diabetes by limiting carbs and exercise. Creat 1.6. Good social support.

▶ Most recent A1c 8.6%

▶ She has great insurance or

▶ She is cash pay or

▶ She hates needles







Older Adults - Considerations



- Reduced life expectancy
- Higher CVD burden
- Reduced GFR
- At risk for adverse events from polypharmacy
- More likely to be compromised from hypoglycemia



✓ Less ambitious targets


√A1c <7.5-8.0%


✓ Focus on drug safety


Diabetes Care 2012;35:1364-1379 Diabetologia 2012;55:1577-1596



Diabetes Education







- ▶ 71 year old woman type 2 diabetes.

 BMI 24. Has been trying to control diabetes by limiting carbs and exercise.
 - Creat 1.6. GFR low 30s. Good social support.
- ▶ Most recent A1c 8.6%
- ▶ Solutions
 - ▶ Great insurance DPP-IV Inhibitor + Basal insulin
 - ▶ She is cash pay or Sulfonylurea, NPH or 70/30
 - ▶ She hates needles Sulfonylurea, DPP-IV Inhibitor if doesn't work, see if she will reconsider insulin






What next?

- ▶ 69 year old male, BMI 31, on Metformin 2000mg a day and Glipizide 40mg a day.
- ▶ A1c 9.1%. Creat 1.2
- ▶ Pt is obese, 11 yr history of diabetes
 - ▶ What next?
 - ▶ Insurance
 - No insurance









What next?

- ▶ 69 year old male, BMI 31, on Metformin 2000mg a day and Glipiz 40mg a day. Wt 100kg
- ▶ A1c 9.1%. Creat 1.2
- ▶ Pt is obese, 11 yr diabetes
- **▶** Solutions
 - ▶ Insurance Add SGLT-2, GLP-1
 - ▶ No insurance Stop Glipizide, keep metformin
 - Add 70/30 insulin 1-2 times a day. 100kg x 0.5 = 50 units daily (30units am/ 20units dinner)





- ▶ 70 yr old, weighs 100kg
- ▶ History of CABG, tobacco
- ▶ A1c 11.3%, BG 400-500 for past weeks
- ▶ Insulin 100+ units Lantus at hs (solostar)
- ▶ Oral Meds: Metformin, Invokana
- ▶ Pt can't afford Lantus insulin pen or Invokana what other option?







Action		Insulin Name	Onset	Peak	Effective Duration	Considerations
		Aspart (Novolog)		30 - 90 min	30 - 90 min < 5 hrs	Bolus insulin lowers after-meal glucose. Efficacy reflected in post- meal BG.
Bolus	Rapid Acting Analogs		5 - 15 min			
boius		Glulisine (Apidra)				
	Short Acting	Regular	30 - 60 min	2 - 3 hrs	5 - 8 hrs	
	Intermediate	NPH	2 - 4 hrs	4 - 10 hrs	10 - 16 hrs	controls BG between
Basal	Laur Artina	Detemir (Levemir) 3 - 8 hrs No peak 6	6 - 24 hrs	meals and HS. Efficacy reflected in		
	Long Acting	Glargine (Lantus)	2 - 4 hrs	No peak	20 - 24 hrs	fasting BG.
	Intermediate	Novolog® Mix 70/30 70/30 = 70% NPA + 30% aspart				Side effects: hypoglycemia, weight gain.
Bolus	+ rapid	1 - 15 min	Dual peaks	10 - 16 hrs	Typical dosing range: 0.5–1.0 units/	
Basal	Intermediate + short	Combo of NPH + Reg 70/30 = 70% NPH + 30% Reg 50/50 = 50% NPH + 50% Reg	30 - 60 min	Dual peaks	10 - 16 hrs	kg body wt/day. Dis- card opened insulin vials after 28 days.

er vial cost	Walmart	Walgreens	Costco
tegular Insulin	\$25*	\$92	\$99
NPH	\$25*	\$92	\$99
70/30	\$25*	\$92	\$101
lumalog	\$200	\$220	\$178
lovolog	\$197	\$217	\$178
Apidra	\$180	\$246	\$178
.evemir	\$300	\$300	\$300
antus	\$226	\$221	\$206

- ▶ 70 yr old, weighs 100kg
- ▶ History of CABG
- ▶ A1c 11.3%, BG 400-500 for past weeks
- ▶ Insulin 100+ units Lantus at hs (solostar).
- ▶ Metformin 1000mg BID
- ▶ What is max basal insulin should he be on?








- ▶ 70 yr old, weighs 100kg
- ▶ History of CABG
- ▶ A1c 11.3%, BG 400-500 for past weeks
- ▶ Insulin 100+ units Lantus at hs (solostar)
- ▶ Metformin 1000mg BID
- What is max basal insulin should he be on?
 - ▶ 100kg x 0.5 = 50 units a day
- ▶ What can we do next to improve BG?





Case Study




What is max basal insulin should he be on?

- ▶ 100kg x 0.5 = 50 units a day
- ▶ What can we do next to improve BG?
 - ▶ Add GLP-1 (Exenatide, Victoza, Trulicity, Tanzeum)
 - ▶ Add bolus insulin to largest meal
 - ▶ Switch him to 70/30 insulin ac breakfast and dinner
 - ▶ Total previous basal dose 100 units
 - ▶ 2/3 in am 65 units am (43 NPH and 22 regular)
 - ▶ 1/3 pre dinner 35 units pm (23 NPH and 12 regular)



Copyright 1999-2014, Diabetes Educational Services, All Rights Reserved.









- ▶ What will inform you of how to proceed?
 - Insurance coverage
 - ▶ His willingness to stick to a complex regimen
 - ▶ His ability to self-monitor
 - ▶ His social support and connection to his medical team





Critical Points

- ▶ Individualize Glycemic targets & BG-lowering
- ▶ Diet, exercise, & education: foundation T2DM therapy
- ▶ Metformin = optimal 1st-line drug.
- ▶ After metformin, data limited. Combo therapy reasonable
- ▶ Ultimately, many T2 patients will require insulin therapy
- ▶ All treatment decisions should be made in conjunction with the patient (focus on preferences, needs & values.)
- CV risk reduction a major focus of therapy.

ADA-EASD Position Statement: Management of Hyperglycemia in T2DM Diabetes Care 2012;35:1364-1379 Diabetologia 2012;55:1577-1596





Thank You



- ▶ Thanks for joining us!
- Please let us know if we can be of more service to you.
- www.DiabetesEd.net





Diabetes Education